BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 37018402)

  • 21. Transgenic mouse with human mutant p53 expression in the prostate epithelium.
    Elgavish A; Wood PA; Pinkert CA; Eltoum IE; Cartee T; Wilbanks J; Mentor-Marcel R; Tian L; Scroggins SE
    Prostate; 2004 Sep; 61(1):26-34. PubMed ID: 15287091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification and characterization of novel ETV4 splice variants in prostate cancer.
    Cosi I; Moccia A; Pescucci C; Munagala U; Di Giorgio S; Sineo I; Conticello SG; Notaro R; De Angioletti M
    Sci Rep; 2023 Mar; 13(1):5267. PubMed ID: 37002241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conditional Deletion of Eaf1 Induces Murine Prostatic Intraepithelial Neoplasia in Mice.
    Pascal LE; Su F; Wang D; Ai J; Song Q; Wang Y; O'Malley KJ; Cross B; Rigatti LH; Green A; Dhir R; Wang Z
    Neoplasia; 2019 Aug; 21(8):752-764. PubMed ID: 31229879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.
    Xing C; Ci X; Sun X; Fu X; Zhang Z; Dong EN; Hao ZZ; Dong JT
    Neoplasia; 2014 Nov; 16(11):883-99. PubMed ID: 25425963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COP1 is a tumour suppressor that causes degradation of ETS transcription factors.
    Vitari AC; Leong KG; Newton K; Yee C; O'Rourke K; Liu J; Phu L; Vij R; Ferrando R; Couto SS; Mohan S; Pandita A; Hongo JA; Arnott D; Wertz IE; Gao WQ; French DM; Dixit VM
    Nature; 2011 May; 474(7351):403-6. PubMed ID: 21572435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia.
    Abdulkadir SA; Magee JA; Peters TJ; Kaleem Z; Naughton CK; Humphrey PA; Milbrandt J
    Mol Cell Biol; 2002 Mar; 22(5):1495-503. PubMed ID: 11839815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deletion of the p16INK4a tumor suppressor and expression of the androgen receptor induce sarcomatoid carcinomas with signet ring cells in the mouse prostate.
    Lee DH; Yu EJ; Aldahl J; Yang J; He Y; Hooker E; Le V; Mi J; Olson A; Wu H; Geradts J; Xiao GQ; Gonzalgo ML; Cardiff RD; Sun Z
    PLoS One; 2019; 14(1):e0211153. PubMed ID: 30677079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, ETV1, and ETV4 on whole-mount radical prostatectomy tissue.
    Lu Z; Williamson SR; Carskadon S; Arachchige PD; Dhamdhere G; Schultz DS; Stricker H; Peabody JO; Jeong W; Chitale DA; Bismar TA; Rogers CG; Menon M; Gupta NS; Palanisamy N
    Prostate; 2020 Jan; 80(1):38-50. PubMed ID: 31584209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The NLR-related protein NWD1 is associated with prostate cancer and modulates androgen receptor signaling.
    Correa RG; Krajewska M; Ware CF; Gerlic M; Reed JC
    Oncotarget; 2014 Mar; 5(6):1666-82. PubMed ID: 24681825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The comprehensive role of E-cadherin in maintaining prostatic epithelial integrity during oncogenic transformation and tumor progression.
    Olson A; Le V; Aldahl J; Yu EJ; Hooker E; He Y; Lee DH; Kim WK; Cardiff RD; Geradts J; Sun Z
    PLoS Genet; 2019 Oct; 15(10):e1008451. PubMed ID: 31658259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate.
    He Y; Johnson DT; Yang JS; Wu H; You S; Yoon J; Lee DH; Kim WK; Aldahl J; Le V; Hooker E; Yu EJ; Geradts J; Cardiff RD; Sun Z
    Oncogene; 2019 Sep; 38(38):6507-6520. PubMed ID: 31358900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Men1 disruption in Nkx3.1-deficient mice results in AR
    Teinturier R; Luo Y; Decaussin-Petrucci M; Vlaeminck-Guillem V; Vacherot F; Firlej V; Bonnavion R; Abou Ziki R; Gherardi S; Goddard I; Gadot N; Bertolino P; Le Romancer M; Zhang CX
    Oncogene; 2021 Feb; 40(6):1118-1127. PubMed ID: 33323967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts.
    Mesquita D; Barros-Silva JD; Santos J; Skotheim RI; Lothe RA; Paulo P; Teixeira MR
    Oncotarget; 2015 Mar; 6(7):5217-36. PubMed ID: 25595908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81.
    Shin S; Kim TD; Jin F; van Deursen JM; Dehm SM; Tindall DJ; Grande JP; Munz JM; Vasmatzis G; Janknecht R
    Cancer Res; 2009 Oct; 69(20):8102-10. PubMed ID: 19789348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ETS factors in prostate cancer.
    Qian C; Li D; Chen Y
    Cancer Lett; 2022 Apr; 530():181-189. PubMed ID: 35033589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor-suppressive activity of Lunatic Fringe in prostate through differential modulation of Notch receptor activation.
    Zhang S; Chung WC; Wu G; Egan SE; Xu K
    Neoplasia; 2014 Feb; 16(2):158-67. PubMed ID: 24709423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis.
    Kim MJ; Bhatia-Gaur R; Banach-Petrosky WA; Desai N; Wang Y; Hayward SW; Cunha GR; Cardiff RD; Shen MM; Abate-Shen C
    Cancer Res; 2002 Jun; 62(11):2999-3004. PubMed ID: 12036903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Id4 deficiency attenuates prostate development and promotes PIN-like lesions by regulating androgen receptor activity and expression of NKX3.1 and PTEN.
    Sharma P; Knowell AE; Chinaranagari S; Komaragiri S; Nagappan P; Patel D; Havrda MC; Chaudhary J
    Mol Cancer; 2013 Jun; 12():67. PubMed ID: 23786676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma.
    Han B; Mehra R; Suleman K; Tomlins SA; Wang L; Singhal N; Linetzky KA; Palanisamy N; Zhou M; Chinnaiyan AM; Shah RB
    Mod Pathol; 2009 Sep; 22(9):1176-85. PubMed ID: 19465903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metformin targets c-MYC oncogene to prevent prostate cancer.
    Akinyeke T; Matsumura S; Wang X; Wu Y; Schalfer ED; Saxena A; Yan W; Logan SK; Li X
    Carcinogenesis; 2013 Dec; 34(12):2823-32. PubMed ID: 24130167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.